Login
Thursday, September 09, 2010

Cumulative Risk Assessment:

 

            The Food Quality Protection Act requires a cumulative risk assessment.  Cumulative risk is the risk due to the exposure to all substances that have a common mechanism of toxicity.  Cumulative risk assessments combine the aggregate risks (from possibly multiple exposure pathways and routes) for all substances that have a common mechanism of toxicity.

 

            Sielken & Associates have helped develop methods that incorporate the relative potency or toxicological equivalence between substances into the cumulative risk assessment.  Toxicological equivalence factors can reflect the exposure duration (e.g., acute, intermediate, subchronic, or chronic)

 

            By using better characterizations of toxicological equivalence and probabilistic exposure characterizations, Sielken & Associates can help avoid the the multiple conservatisms associated with the regulatory default assessments that exaggerate cumulative risks.

3. Human Health Risk Assessment
3.1     
Quantitative Risk Assessment and Statistical Analysis
3.2      Importance of Dose and Dose-Response Relationships
3.3      Misuse of Regulatory Upper-Bound Risk Characterizations
3.4      Risk Characterization Choices and Risk Exaggeration
3.5      A Better Approach to Cancer Risk Characterization
3.6      Overview of Background, Motivation, and Statistical Methods for Margin-of-Exposure Characterizations of Cancer Risks
           3.6.1    Importance of Dose
           3.6.2    Dose-Response Modeling
           3.6.3    Dose-Response Models
           3.6.4    Maximum Likelihood Estimation
           3.6.5    
Multistage Model
           3.6.6    Example of Fitted Multistage Model
           3.6.7    Potency
           3.6.8    Linearized Multistage Model
           3.6.9    Overstatement of Risks by the Linearized Multistage Model
           3.6.10  Adverse Impacts of the Variability in the Magnitude of the Bias in the Linearized Multistage Model's Overstatement of Risks
           3.6.11  Non-Responsiveness of the Linearized Multistage Model to Data
           3.6.12  Ranking Relative Risks
           3.6.13  Added Risk versus Extra Risk
           3.6.14  Need for a Better Dose-Response Characterization
           3.6.15  Better Dose-Response Characterization
           3.6.16  Benchmark Doses
           3.6.17  Responsiveness of Benchmark Doses Data Versus the Relative Non-Responsiveness of the Regulatory Upper-Bound Potency Q1* based on the Linearized Multistage Model
           3.6.18  Recommended Dose-Response Characterization
           3.6.19  Margin-of-Exposure Characterizations
           3.6.20  Conclusion
           3.6.21  Figures 1 to 16
3.7      Innovative Risk Assessment
3.8      Components of High-to-Low-Dose Extrapolation and Dose-Response Modeling
3.9      Probabilistic Exposure Assessment
3.10    Aggregate Risk Assessment
3.11    Cumulative Risk Assessment
3.12    Example Activities